Decreased sensorineural hearing. Unspecified sensorineural hearing loss
Conditions
Interventions
Intervention 1: Intervention group: Rivaroxaban 10 mg tablets of the ?Arena company are received daily for 10 days. Intervention 2: Control group: Placebo tablets with the same shape and color are ta
Sponsors
Esfahan University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Diagnosis of SNHL by an ENT specialist Reduction of more than 30 dB in hearing at least 3 frequencies Body mass index between 18-30 kg per square meter Negative pregnancy test in women of reproductive age 15-35 years Normal coagulation tests Normal renal function Regular visits for follow up Consent to enter the study
Exclusion criteria
Exclusion criteria: Previous hemorrhagic diseases such as intracranial hemorrhage Previous coagulation diseases History of previous thrombosis anywhere on the body Active stomach ulcers History of psychiatric diseases Any previous illness or surgery on the ears Any signs of inflammation or infection of the ear on examination History of hearing loss Meniere's disease Recent vocal or compressive trauma Underlying disease that may be the cause of SNHL, such as trauma, autotoxic drugs, infection, etc Blood pressure higher than 180/110 Uncontrolled diabetes Hypersensitivity reaction to corticosteroids Taking drugs such as methadone
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pure tone audiometry Level. Timepoint: Beginning and end of the study. Method of measurement: Audiometric device.;Word recognition score level. Timepoint: Beginning and end of the study. Method of measurement: Audiometric device. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactEhsan moshtaghi
Esfahan University of Medical Sciences
Outcome results
None listed